

BIOCON GROUP

FACT SHEET

September - 2017

| BIOCON LIMITED (CONSOLIDATED) | | |
|---|---------------------|-----------------------|
| BALANCE SHEET | | |
| | (Rs Cr) | |
| | Sep 30, 2017 | March 31, 2017 |
| ASSETS | | |
| Non-current assets | | |
| (a) Property, plant and equipment | 3,603 | 3,553 |
| (b) Capital work-in-progress | 574 | 533 |
| (c) Investment property | 1 | 1 |
| (d) Goodwill | 26 | 26 |
| (e) Other intangible assets | 41 | 46 |
| (f) Intangible assets under development | 385 | 306 |
| (g) Investments in associates and a joint venture | 52 | 42 |
| (h) Financial assets | - | - |
| Investments | - | 146 |
| Derivative assets | 122 | 109 |
| Other financial assets | 24 | 20 |
| (i) Income-tax asset, net | 101 | 90 |
| (j) Deferred tax asset, net | 199 | 197 |
| (k) Other non-current assets | 312 | 278 |
| | 5,440 | 5,347 |
| Current assets | | |
| (a) Inventories | 716 | 635 |
| (b) Financial assets | | |
| Investments | 1,295 | 1,065 |
| Trade receivables | 945 | 883 |
| Cash and cash equivalents | 485 | 710 |
| Other bank balances | 200 | 334 |
| Derivative assets | 82 | 106 |
| Other financial assets | 130 | 155 |
| (c) Other current assets | 182 | 159 |
| | 4,035 | 4,047 |
| TOTAL | 9,475 | 9,394 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Share capital | 300 | 100 |
| (b) Other equity | 4,639 | 4,738 |
| Equity attributable to equity holders of the Company | 4,939 | 4,838 |
| Non-controlling interest | 412 | 376 |
| | 5,351 | 5,214 |
| Non-current liabilities | | |
| (a) Financial liabilities | | |
| Borrowings | 2,055 | 2,108 |
| Derivative liability | 7 | 6 |
| Other financial liabilities | - | - |
| (b) Provisions | 39 | 36 |
| (c) Other non-current liabilities | 338 | 352 |
| | 2,439 | 2,502 |
| Current liabilities | | |
| (a) Financial liabilities | | |
| Borrowings | 212 | 97 |
| Trade payables | 822 | 740 |
| Derivative liability | 7 | 6 |
| Other financial liabilities | 297 | 326 |
| (b) Short-term provision | 53 | 47 |
| (c) Income tax liability, net | 96 | 96 |
| (d) Other current liabilities | 198 | 366 |
| | 1,685 | 1,678 |
| TOTAL | 9,475 | 9,394 |

| BIOCON LIMITED (CONSOLIDATED) | | | |
|---|--------------|--------------|--------------|
| PROFIT & LOSS STATEMENT | | | (Rs. Crores) |
| Particulars | H1 FY 18 | H1 FY 17 | Variance |
| INCOME | | | |
| Small molecules | 713 | 839 | -15% |
| Biologics | 340 | 316 | 7% |
| Branded formulations | 306 | 295 | 4% |
| Research services | 626 | 578 | 8% |
| Inter-segment | (83) | (81) | 3% |
| Revenue from operations # | 1,902 | 1,947 | -2% |
| Other income | 105 | 79 | 32% |
| TOTAL REVENUE | 2,007 | 2,026 | -1% |
| EXPENDITURE | | | |
| Material & Power costs | 833 | 821 | 1% |
| Staff costs | 397 | 330 | 20% |
| Research & Development expenses* | 112 | 117 | -4% |
| Other expenses | 186 | 176 | 5% |
| Manufacturing, staff & other expenses | 1,528 | 1,444 | 6% |
| EBITDA | 479 | 582 | -18% |
| Interest & Finance charges | 30 | 12 | 145% |
| Depreciation & Amortisation | 192 | 134 | 43% |
| Share of profit in JV | (10) | (10) | 0% |
| PBT BEFORE EXCEPTIONAL ITEM | 267 | 446 | -40% |
| Exceptional item, Net | - | - | - |
| PBT | 267 | 446 | -40% |
| Taxes | 80 | 97 | -17% |
| NET PROFIT BEFORE MINORITY INTEREST | 187 | 349 | -46% |
| Minority interest | 37 | 36 | 3% |
| NET PROFIT FOR THE PERIOD | 150 | 313 | -52% |
| EPS Rs. | 2.5 | 5.2 | |
| <i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i> | | | |
| # Licensing Income | 9 | 50 | |
| * Gross Research & Development expenses | 189 | 204 | |

| BIOCON LIMITED (CONSOLIDATED) | | | (Rs. Crores) |
|---|--------------|-------------|--------------|
| PROFIT & LOSS STATEMENT | | | |
| Particulars | Q2 FY 18 | Q2 FY 17 | Variance |
| INCOME | | | |
| Small molecules | 351 | 403 | -13% |
| Biologics | 156 | 156 | 0% |
| Branded formulations | 176 | 137 | 29% |
| Research services | 335 | 303 | 11% |
| Inter-segment | (49) | (44) | 10% |
| Revenue from operations # | 969 | 955 | 2% |
| Other income | 50 | 38 | 32% |
| TOTAL REVENUE | 1,019 | 993 | 3% |
| EXPENDITURE | | | |
| Material & Power costs | 423 | 383 | 11% |
| Staff costs | 204 | 166 | 23% |
| Research & Development expenses* | 54 | 65 | -17% |
| Other expenses | 105 | 101 | 4% |
| Manufacturing, staff & other expenses | 786 | 715 | 10% |
| EBITDA | 233 | 278 | -16% |
| Interest & Finance charges | 14 | 7 | 112% |
| Depreciation & Amortisation | 93 | 68 | 37% |
| Share of profit in JV | (6) | (5) | 28% |
| PBT BEFORE EXCEPTIONAL ITEM | 132 | 208 | -37% |
| Exceptional item, Net | - | - | - |
| PBT | 132 | 208 | -37% |
| Taxes | 43 | 41 | 2% |
| NET PROFIT BEFORE MINORITY INTEREST | 89 | 167 | -47% |
| Minority interest | 20 | 20 | 3% |
| NET PROFIT FOR THE PERIOD | 69 | 147 | -53% |
| EPS Rs. | 1.1 | 2.4 | |
| <i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i> | | | |
| # Licensing Income | 1 | 33 | |
| * Gross Research & Development expenses | 93 | 113 | |

| BIOCON LIMITED (CONSOLIDATED) | | | (Rs. Crores) |
|---|--------------|-------------|-------------------|
| PROFIT & LOSS STATEMENT | | | |
| Particulars | Q2 FY 18 | Q1 FY 18 | Variance IndAS |
| INCOME | | | |
| Small molecules | 351 | 363 | -3% |
| Biologics | 156 | 184 | -15% |
| Branded formulations | 176 | 130 | 35% |
| Research services | 335 | 291 | 15% |
| Inter-segment | (49) | (34) | 41% |
| Revenue from operations # | 969 | 934 | 4% |
| Other income | 50 | 54 | -6% |
| TOTAL REVENUE | 1,019 | 988 | 3% |
| EXPENDITURE | | | |
| Material & Power costs | 423 | 410 | 3% |
| Staff costs | 204 | 193 | 6% |
| Research & Development expenses* | 54 | 58 | -7% |
| Other expenses | 105 | 81 | 31% |
| Manufacturing, staff & other expenses | 786 | 742 | 6% |
| EBITDA | 233 | 246 | -5% |
| Interest & Finance charges | 14 | 16 | -14% |
| Depreciation & Amortisation | 93 | 99 | -5% |
| Share of profit in JV | (6) | (4) | 44% |
| PBT BEFORE EXCEPTIONAL ITEM | 132 | 135 | -2% |
| Exceptional item, Net | - | - | - |
| PBT | 132 | 135 | -2% |
| Taxes | 43 | 38 | 13% |
| Taxes on exceptional item | - | - | 0% |
| NET PROFIT BEFORE MINORITY INTEREST | 89 | 97 | -8% |
| Minority interest | 20 | 16 | 24% |
| NET PROFIT FOR THE PERIOD | 69 | 81 | -15% |
| EPS Rs. | 1.1 | 1.4 | |
| <i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i> | | | |
| # Licensing Income | 1 | 8 | |
| * Gross Research & Development expenses | 93 | 96 | |